Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Neurourol Urodyn. 2023 Jun 3;42(6):1214–1226. doi: 10.1002/nau.25222

Table 4.

Summary of model performance

C-statistic [95% CI] (0 to 1, higher is better) Brier Score [95% CI] (0 to 1, lower is better)
Outcome: Level of Treatment
Proportional odds model
 Overall 0.686 [0.657, 0.741] NA a
 Level 1–4 vs. 0 0.686 [0.657, 0.742] 0.154 [0.126, 0.175]
 Level 2–4 vs. 0–1 0.685 [0.658, 0.741] 0.217 [0.193, 0.226]
 Level 3–4 vs. 0–2 0.686 [0.658, 0.741] 0.162 [0.137, 0.180]
 Level 4 vs. 0–3 0.684 [0.656, 0.741] 0.063 [0.040, 0.084]
Separate binary logistic regression models
 Level 1–4 vs. 0 0.663 [0.653, 0.712] 0.158 [0.146, 0.173]
 Level 2–4 vs. 0–1 0.702 [0.664, 0.779] 0.216 [0.191, 0.226]
 Level 3–4 vs. 0–2 0.796 [0.762, 0.868] 0.159 [0.127, 0.173]
 Level 4 vs. 0–3 0.673 [0.615, 0.863] 0.065 [0.037, 0.084]
Outcome: Time to OAB Medication Discontinuation
Cox proportional hazard model 0.671 [0.579, 0.766] 0.185 [0.151, 0.247] b
Outcome: Sling
Binary logistic regression 0.823 [0.829, 0.834] 0.091 [0.089, 0.091]

Note: Brier score captures both discrimination and calibration. It ranges between 0 and 1, with lower score indicating better model performance. C-statistic assess discrimination and ranges between 0 and 1, with higher score indicating better discrimination performance.

a

Brier score is inappropriate for ordinal outcome.

b

Brier score evaluated at 6-month since OAB medication initiation or baseline if medication was started before baseline. It is not corrected for bias.

CI, confidence interval; OAB, overactive bladder